NHC Quote, Financials, Valuation and Earnings

American Shared Hospital Services has a net margin of 1.65% compared to National Healthcare's net margin of -2.96%. National Healthcare's return on equity of 10.72% beat American Shared Hospital Services's return on equity of 13.75%.

National Healthcare has a consensus price target of --, signalling downside risk potential of --. On the other hand American Shared Hospital Services has an analysts' consensus of $4.84 which suggests that it could grow by 74.73%. Given that American Shared Hospital Services has higher upside potential than National Healthcare, analysts believe American Shared Hospital Services is more attractive than National Healthcare.

National Healthcare has a beta of 0.422, which suggesting that the stock is 57.822% less volatile than S&P 500. In comparison American Shared Hospital Services has a beta of 0.424, suggesting its less volatile than the S&P 500 by 57.593%.

National Healthcare has a quarterly dividend of $0.61 per share corresponding to a yield of 2.6%. American Shared Hospital Services offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. National Healthcare pays 36.27% of its earnings as a dividend. American Shared Hospital Services pays out -- of its earnings as a dividend. National Healthcare's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

National Healthcare quarterly revenues are $369.4M, which are larger than American Shared Hospital Services quarterly revenues of $7M. National Healthcare's net income of $6.1M is higher than American Shared Hospital Services's net income of -$207K. Notably, National Healthcare's price-to-earnings ratio is 14.37x while American Shared Hospital Services's PE ratio is 7.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for National Healthcare is 1.13x versus 0.64x for American Shared Hospital Services. Usually stocks with elevated PS ratios are considered overvalued.

Cryo-Cell International has a net margin of 1.65% compared to National Healthcare's net margin of 3.55%. National Healthcare's return on equity of 10.72% beat Cryo-Cell International's return on equity of --.

National Healthcare has a consensus price target of --, signalling downside risk potential of --. On the other hand Cryo-Cell International has an analysts' consensus of $8.50 which suggests that it could grow by 50.44%. Given that Cryo-Cell International has higher upside potential than National Healthcare, analysts believe Cryo-Cell International is more attractive than National Healthcare.

National Healthcare has a beta of 0.422, which suggesting that the stock is 57.822% less volatile than S&P 500. In comparison Cryo-Cell International has a beta of 0.607, suggesting its less volatile than the S&P 500 by 39.282%.

National Healthcare has a quarterly dividend of $0.61 per share corresponding to a yield of 2.6%. Cryo-Cell International offers a yield of 8.85% to investors and pays a quarterly dividend of $0.25 per share. National Healthcare pays 36.27% of its earnings as a dividend. Cryo-Cell International pays out 502.5% of its earnings as a dividend. National Healthcare's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Cryo-Cell International's is not.

National Healthcare quarterly revenues are $369.4M, which are larger than Cryo-Cell International quarterly revenues of $8M. National Healthcare's net income of $6.1M is higher than Cryo-Cell International's net income of $282.9K. Notably, National Healthcare's price-to-earnings ratio is 14.37x while Cryo-Cell International's PE ratio is 565.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for National Healthcare is 1.13x versus 1.44x for Cryo-Cell International. Usually stocks with elevated PS ratios are considered overvalued.

InnovAge Holding has a net margin of 1.65% compared to National Healthcare's net margin of -6.33%. National Healthcare's return on equity of 10.72% beat InnovAge Holding's return on equity of -8.76%.

National Healthcare has a consensus price target of --, signalling downside risk potential of --. On the other hand InnovAge Holding has an analysts' consensus of $5.25 which suggests that it could grow by 80.41%. Given that InnovAge Holding has higher upside potential than National Healthcare, analysts believe InnovAge Holding is more attractive than National Healthcare.

National Healthcare has a beta of 0.422, which suggesting that the stock is 57.822% less volatile than S&P 500. In comparison InnovAge Holding has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

National Healthcare has a quarterly dividend of $0.61 per share corresponding to a yield of 2.6%. InnovAge Holding offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. National Healthcare pays 36.27% of its earnings as a dividend. InnovAge Holding pays out -- of its earnings as a dividend. National Healthcare's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

National Healthcare quarterly revenues are $369.4M, which are larger than InnovAge Holding quarterly revenues of $209M. National Healthcare's net income of $6.1M is higher than InnovAge Holding's net income of -$13.2M. Notably, National Healthcare's price-to-earnings ratio is 14.37x while InnovAge Holding's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for National Healthcare is 1.13x versus 0.49x for InnovAge Holding. Usually stocks with elevated PS ratios are considered overvalued.

Sonida Senior Living has a net margin of 1.65% compared to National Healthcare's net margin of -5.99%. National Healthcare's return on equity of 10.72% beat Sonida Senior Living's return on equity of -4.58%.

National Healthcare has a consensus price target of --, signalling downside risk potential of --. On the other hand Sonida Senior Living has an analysts' consensus of $25.00 which suggests that it could grow by 19.56%. Given that Sonida Senior Living has higher upside potential than National Healthcare, analysts believe Sonida Senior Living is more attractive than National Healthcare.

National Healthcare has a beta of 0.422, which suggesting that the stock is 57.822% less volatile than S&P 500. In comparison Sonida Senior Living has a beta of 1.279, suggesting its more volatile than the S&P 500 by 27.886%.

National Healthcare has a quarterly dividend of $0.61 per share corresponding to a yield of 2.6%. Sonida Senior Living offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. National Healthcare pays 36.27% of its earnings as a dividend. Sonida Senior Living pays out -136.86% of its earnings as a dividend. National Healthcare's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

National Healthcare quarterly revenues are $369.4M, which are larger than Sonida Senior Living quarterly revenues of $91.9M. National Healthcare's net income of $6.1M is higher than Sonida Senior Living's net income of -$5.5M. Notably, National Healthcare's price-to-earnings ratio is 14.37x while Sonida Senior Living's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for National Healthcare is 1.13x versus 0.98x for Sonida Senior Living. Usually stocks with elevated PS ratios are considered overvalued.